MicroRNAs (miRNAs) regulate cell proliferation and differentiation by controlling the expression of proteins involved in many signaling pathways. Recent studies have shown that dysregulation of miRNA expression is associated with increased tumorigenicity and a poor prognosis in several types of cancers. The miRNA let-7b is one of the severely downregulated miRNAs in mixed-lineage leukemia (MLL)-rearranged acute lymphoblastic leukemia (ALL) patients. In vitro transfection of leukemogenic MLL fusion genes into human embryonic kidney-293 cells suppressed let-7b expression. In leukemic cells with an MLL fusion gene, the regulatory region for let-7b expression was hypermethylated, and its expression was partially recovered after culturing the cells with the demethylating agent 5-azacitidine. These results suggest that loss of let-7b expression may be one of the consequences of oncogenic MLL fusion proteins, and contributes to leukemogenesis possibly through the upregulation of let-7b-regulated target genes with leukemogenic potential in hematopoietic cells. The enforced expression of let-7b in ALL cell lines with an MLL fusion gene inhibited their growth, indicating the possible use of let-7b as a new therapeutic tool for refractory infant ALL with an MLL fusion gene.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) in infants is often accompanied by hyperleukocytosis, hepatosplenomegaly and extramedullary leukemic infiltration at initial diagnosis. 1 Biologically, leukemic cells are frequently characterized by chromosome translocations involving 11q23, resulting in the rearrangement of the mixed-lineage leukemia (MLL) gene, which is associated with a poor outcome in most treatment programs. 2 To date, more than 50 genes have been identified at the translocation breakpoint of the MLL gene, which produce leukemogenic fusion proteins with a common structure that always contains the N-terminal portion of MLL. The activation of some oncogenes that drive cellular proliferation or perturb differentiation, such as HOXA9, has been identified as one of the effects of MLL fusion genes in hematopoietic precursors/progenitors, and is thought to be involved in the leukemogenic process. 3 MicroRNAs (miRNAs), small non-coding RNAs of 20-24 nucleotides, have recently been recognized as important molecules that regulate the expression of many proteins by translation inhibition or cleavage of their mRNA transcripts. miRNAs are involved in many biological pathways, including cell growth and hematopoietic cell differentiation. Several studies have shown that dysregulation of miRNA expression is a common feature in human cancers, including leukemia, indicating that abnormal expression of miRNAs has an important role in oncogenesis. 4 Recently, Schotte et al. 5 reported the array-based analysis of miRNA expression in pediatric ALL samples. They identified let-7b as one of the discriminative miRNAs of MLL-rearranged ALL.
The miRNA let-7 was originally identified in Caenorhabditis elegans as a regulator of cellular proliferation. 6 There are at least nine individual members of the let-7 family in mammals, and the sequence and function of this family are highly conserved in mammals. Members of the let-7 family functionally inhibit the expression of several oncogenes such as the Ras family, 7 
HMGA2
8,9 and c-Myc, 10, 11 and cell cycle regulators such as CDC25A, 12 CDK6 and cyclin D2. 13 These findings indicate that the miRNAs of the let-7 family may function as tumor suppressors. In accordance with this hypothesis, several let-7 genes are located in regions that are frequently deleted in human cancers, 14 and let-7 expression is downregulated in some malignancies such as lung cancer. 15, 16 When ectopically expressed, let-7 miRNA can repress cellular proliferation and tumor development. 8, 13, 17 We show here that let-7b is downregulated in leukemic cells with an MLL rearrangement via DNA hypermethylation of its regulatory region. In vitro experiments showed that downregulation of let-7b may be one of the consequences of MLL fusion protein activity, possibly involved in the first hit pathway of leukemogenesis that is driven by an MLL fusion oncoprotein, such as the dysregulation of the HOX gene family.
MATERIALS AND METHODS

Cell lines
Cell lines established from ALL patients were used in this study. These included six cell lines with MLL gene rearrangement established from infant ALL patients: KOCL45, KOCL58 and KOCL69, which carry an MLL-AF4 gene fusion, KOPB26, which carry an MLL-AF9 gene fusion, and KOCL44 and KOPN1, which carry an MLL-ENL fusion gene. The KOPN79 and REH cell lines, which carry a TEL-AML1 fusion gene, and YAMN90, which carry an E2A-PBX1 fusion gene, were used as MLL germline control cells. The details of the cell lines are described elsewhere. [18] [19] [20] [21] [22] All cell lines were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum at 37 1C in 5% CO 2 in air.
Patient samples
Peripheral blood or bone marrow cells were collected from ALL infants at diagnosis. According to the Declaration of Helsinki, written informed consent was obtained from the parents, and all research was approved by the institutional review board. Mononuclear cells were separated by FicollPaque density centrifugation (GE Healthcare, Piscataway, NJ, USA). More than 90% of the isolated cells were leukemic cells in all samples used in this study.
TaqMan miRNA assay and quantitative reverse transcriptase-PCR Total RNA, including miRNA, was extracted from the leukemic samples and cell lines using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) with DNase treatment, according to the manufacturer's instructions. The TaqMan real-time reverse transcriptase-PCR (RT-PCR) method was used to quantify the expression of let-7b miRNA. Reverse transcription was performed using the TaqMan miRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA), and the expression of mature let-7b was measured using the TaqMan miRNA Assay (Applied Biosystems, Assay ID 002619). RNU44 expression (Applied Biosystems, Assay ID 002619) was also measured and used as an internal reference to normalize let-7b expression.
For RT-PCR and real-time quantification of genes other than miRNAs, 1 mg of total RNA was reverse transcribed using the PrimeScript RT-PCR Kit (TaKaRa, Otsu, Japan). Real-time PCR was performed using SYBR Premix Ex Taq II (TaKaRa) on an Applied Biosystems 7500 Real-Time PCR System with the PCR conditions recommended by the supplier. All measurements were performed in duplicate, and the difference in the duplicate threshold cycle was less than 1 cycle in all samples tested. All experiments were repeated at least three times, and the data were statistically analyzed using the t-test. The primers used for real-time PCR are summarized in Supplementary Table 1 .
Transfection of MLL fusion genes
The neomycin resistance gene of pMSCVneo vector (Clontech, Mountain View, CA, USA) was replaced with the EGFP sequence (pMSCV-EGFP vector), and coding regions of the MLL fusion genes (MLL-AF4, MLL-ENL and MLL-AF9) were introduced into the multi-cloning site of the pMSCV-EGFP vector. Briefly, the 5 0 -portion of the MLL coding region (nucleotides 24-3774 in RefSeq NM_001197104) was removed from the MSCV2.1-MLL-GPHN vector 23 using EcoRI and BamHI. The rest of the MLL coding region (nucleotides 3775-4355) and the fusion partner sequence (AF4: nucleotides 1446-4040 in NM_005935; AF9/MLLT3: nucleotides 1321-1966 in NM_004529; ENL/MLLT1: nucleotides 177-1844 in NM_005934), including the junction sequences, were amplified from the cDNAs of leukemic cell lines and patient samples by PCR using partner gene-specific reverse primers containing XhoI restriction sites. The PCR products were digested using XhoI and BamHI. These PCR products and the 5 0 -portion of MLL were introduced into the pMSCV-EGFP vector to form the full-length MLL fusion gene in the vector. Primers used for vector construction are listed in Supplementary Table 1. All constructs were checked by direct sequencing to exclude mutations introduced during their construction. Transient transfection of human embryonic kidney (HEK)-293 cells was performed using Effectene (Qiagen). At 72-96 h after transfection, enhanced green fluorescent protein (EGFP)-positive cells were sorted on a FACSAria Cell Sorter (BD Biosciences, San Jose, CA, USA), and total RNA, including miRNA, was extracted from the sorted EGFP-positive cells using the miRNeasy Mini Kit (Qiagen) as described above. In all FACS sorting experiments, TO-PRO-3 iodide (Molecular Probes, Eugene, OR, USA) was used to exclude dead cells.
DNA extraction, bisulfite modification and methylation-specific real-time PCR DNA was extracted from the leukemic samples and ALL cell lines using standard procedures. After DNA extraction, 100 ng to 1 mg of DNA was modified with sodium bisulfite for DNA methylation analysis using the EpiTect Bisulfite Kit (Qiagen) according to the manufacturer's instructions. After bisulfite treatment, the promoter region of a gene located upstream from the let-7b coding region (RP4-695O20_B.10) was amplified using a specific primer pair with an EcoRI recognition site at the 5 0 -end. PCR products were electrophoresed and purified using the QIAquick Gel Extraction Kit (Qiagen), digested with EcoRI, and cloned into the pBluescript II SK ( þ ) vector (Stratagene, Santa Clara, CA, USA). Following bacterial transformation, at least 20 individual colonies were subjected to sequence analysis to detect DNA methylation.
The DNA methylation status was also analyzed by methylation-specific, real-time PCR of bisulfite-modified DNA. Primers were designed to amplify methylated or unmethylated CpG dinucleotides in the promoter region of the gene upstream of let-7b. Real-time PCR was performed using the KAPA SYBR FAST qPCR Kit (Kapa Biosystems, Boston, MA, USA), according to the manufacturer's instructions, on an Applied Biosystems 7500 Real-time PCR System. All the bisulfite-PCR primers were designed using the Methyl Primer Express software (Applied Biosystems). The validity and sensitivity of methylation-specific quantitative PCR was confirmed using standard amplification curves generated from serially diluted plasmid vector DNA containing methylated or unmethylated DNA obtained after bisulfite sequencing analysis of ALL cell lines (Supplementary Figure 1) . Details of the primers for bisulfite-PCR are provided in Supplementary Table 1.
Demethylating agent 5-Azacitidine (Sigma-Aldrich, St Louis, MO, USA) was used at a concentration of 2 mM in cell culture. The ALL cell lines were cultured with 5-azacitidine for 7 days. The cells were stained with anti-CD10-FITC (BioLegend, San Diego, CA, USA), and the expression of CD10 after 5-azacitidine treatment was analyzed using a FACSCalibur Flow Cytometer (BD Biosciences). In addition, total RNA (including miRNA) was extracted as mentioned above and subjected to quantitative real-time PCR.
MTT assay
For the introduction of let-7b miRNA into leukemic cell lines, genomic sequences containing the let-7b coding region (691 bp in length) were amplified by PCR and inserted at the 3 0 -end of the EGFP sequence in the pEGFP-C3 expression vector (Clontech, pEGFP-let-7b). In transfected cells, the let-7b coding sequence is transcribed from the 3 0 -untranslated region (UTR) of the EGFP transcript, producing mature let-7b after miRNA processing. Leukemic cell lines were transfected with this pEGFP-let-7b construct or the pEGFP-C3 empty vector using the Amaxa Nucleofector II Kit V (Lonza, Basel, Switzerland). Twenty-four hours after transfection, the EGFP-positive fraction was sorted using FACSAria and 2 to 6 Â 10 4 cells were plated into each well of a 96-well plate in 100 ml culture medium. After 48 h, 10 ml of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Dojindo, Kumamoto, Japan) solution, 5 mg/ml in phosphatebuffered saline, was added to each well and incubated at 37 1C for another 6 h. The cells were then lysed by adding 100 ml lysis solution (0.04 N HCl in 2-propanol) per well. The absorbance of each well at 595 nm was measured using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The background value (the absorbance of the control well containing medium without cells after the addition of MTT and the lysis solution) was subtracted from all measured values. All experiments were performed in quadruplicate and repeated at least three times.
Statistical analysis
Statistical significance was determined by calculating two-tailed P-values using the t-test.
RESULTS
In this study, we first examined the expression of let-7b in ALL patients and cell lines by quantitative RT-PCR using the TaqMan miRNA assay for let-7b. As shown in Figure 1a , let-7b was significantly suppressed in MLL-rearranged leukemic samples, compared with samples with germline MLL. Considering that the expression level of let-7b in peripheral blood mononuclear cells Suppression of let-7b by DNA hypermethylation M Nishi et al was set as 1 in Figure 1a , the expression of let-7b was lower in infant ALL samples irrespective of the status of the MLL gene.
Cell lines with an MLL rearrangement (except for the MLL-ENLbearing cell line KOCL44) also showed decreased let-7b expression compared with the cell line with TEL-AML1 or E2A-PBX1 (Figure 1b ). The expression of pre-let7b (miRBase accession no. MI0000063), the precursor of let-7b with a stem-loop structure before its processing by Dicer, was also downregulated in the ALL cell lines with an MLL rearrangement, except for the KOCL44 cell line, exactly corresponding to the expression of mature let-7b (Supplementary Figure 2) . This indicates that the loss of let-7b expression may be because of the suppression of gene expression rather than reduced let-7b miRNA processing.
The miRNA let-7b is located on chromosome 22q13 in the 3 0 -UTR of a gene with an unknown function (RP4-695O20_B.10, Ensembl gene ID, ENSG00000197182). We performed PCR and quantitative PCR to examine whether genomic deletion around the let-7b coding region was responsible for its low expression. In all cases examined, no deletions were detected in the region, indicating that transcriptional regulation of let-7b may be responsible for the loss of its expression in MLL-rearranged leukemic cells (data not shown).
To determine whether MLL fusion proteins regulated the expression of let-7b, we measured let-7b expression after the introduction of MLL fusion genes into HEK293 cells, which express endogenous let-7b. The expression of EGFP and MLL fusion was simultaneously driven so that MLL fusion-transfected cells could easily be separated by cell sorting. At 72-96 h after transfection, the EGFP-positive population in each set of transfected cells was separated by cell sorting (Figure 2a) , and let-7b expression was measured by quantitative RT-PCR. As shown in Figure 2b , let-7b expression was significantly downregulated by the expression of all MLL fusion proteins. The expression of MLL fusion genes in the sorted EGFP-positive cells was examined by RT-PCR, and all samples, except the mock-transfected cells, expressed MLL fusion transcripts of the predicted size (Supplementary Figure 3) . The results at 72 and 96 h after transfection were comparable.
Infant ALL with an MLL gene rearrangement is characterized by the loss of surface CD10 expression, which is a hallmark of MLL gene rearrangements. 2, 24, 25 The suppression of CD10 expression in MLL-rearranged infant ALL is reported to be caused by the dense methylation of its promoter. 26 To explore the possibility that let-7b expression was regulated by DNA methylation in MLL-rearranged infant ALL, the methylation status of the let-7b locus was examined by bisulfite-PCR and sequencing. The let-7b coding region was highly methylated in all the ALL cell lines studied, irrespective of the MLL gene status (data not shown). The let-7b is located in the 3 0 -UTR of an uncharacterised gene (RP4-695O20_B.10, illustrated in Figure 3a ) that has six exons producing several transcripts (Ensembl transcript ID, ENST00000360737, ENST00000381051, ENST00000443490 and ENST00000435439). The expression of RP4-695O20_B.10 in the ALL cell lines was examined using quantitative RT-PCR. Although the TEL-AML1-positive cell lines KOPN79 and REH showed weak, but definite, expression of the gene, it was almost undetectable in the cell lines with an MLL fusion gene, KOCL45 and KOCL69 ( Figure 3b ). As this gene had three possible first exons (designated as 1a, 1b and 1c in Figure 3a ), the expression levels of transcripts with each of the first exons was analyzed by quantitative RT-PCR in the KOPN79 and REH cell lines. As shown in Figure 3c , the transcript containing exon 1a was the most abundant in the let-7b-expressing KOPN79 and REH cell lines. RT-PCR analysis with primers located in exon 1a and exon 6, which is followed by the 3 0 -UTR that contains the let-7b sequence, revealed the expression of a transcript containing both exons (Supplementary Figure 4) , indicating that the promoter region of exon 1a may also act as the regulatory region of let-7b.
The DNA methylation status of the upstream region of exon 1a was analyzed using bisulfite-PCR analysis. Three major CpG islands were identified by the Methyl Primer Express software (Applied Biosystems), and the proximal CpG island was selected for further analysis. The 11 CpG dinucleotides within this region were analyzed by bisulfite-PCR. In the KOCL45 cell line with the MLL-AF4 fusion gene, all the cytosines in this CpG island were methylated, presenting a striking contrast to the KOPN79 cell line with the TEL-AML1 fusion gene in which almost all the CpG sites were unmethylated (Figure 3d ). These results were also confirmed by methylation-specific real-time quantitative PCR analysis using bisulfite-treated DNA. In the KOCL45 and KOCL69 cell lines, only methylated CpG-specific amplification was observed, and the amplification of unmethylated CpG was virtually negligible (Figure 4a ). By contrast, the KOPN79 cell line mainly showed Suppression of let-7b by DNA hypermethylation M Nishi et al dinucleotides, but the proportion of unmethylated CpG dinucleotides was always sufficient to drive significant residual promoter activity for let-7b expression in these cells (Figures 3d and 4a) . DNA methylation is mediated by DNA methyltransferases (DNMTs). Mammals have three DNMTs as follows: DNMT1, DNMT3A and DNMT3B. 27 DNMT mutations and overexpression have been reported in cancer, suggesting that it may be one of the mechanisms underlying the aberrant methylation status in human cancer. 28 Expression of DNMTs (DNMT1, DNMT3A and DNMT3B) was examined in MLL-rearranged leukemic cell lines by quantitative RT-PCR. DNMT expression levels varied between cell lines; however, DNMTs were not specifically overexpressed in MLL-rearranged leukemic cell lines compared with leukemic cells with germline MLL or normal peripheral blood lymphocytes (Supplementary Figure 5A) . Patient samples were not analyzed because sufficient amounts of samples were not available; however, data mining of expression array data published by Stam et al. 29 showed that DNMTs were not overexpressed in MLL-rearranged leukemia compared with MLL germline leukemia. Expression of DNMTs was analyzed after forced expression of MLL fusion genes in HEK293 cells. No changes in expression were observed in the control and MLL fusion genetransfected samples, indicating that aberrant expression of DNMTs is not responsible for downregulation of let-7b in HEK293 cells (Supplementary Figure 5B) .
We next examined the effect of the demethylating agent 5-azacitidine on let-7b expression in the KOCL58 and KOPN1 cell lines, which showed heavily repressed expression of let-7b among the MLL fusion-positive ALL cell lines (Figure 1b) . CD10, a membrane metallo-endopeptidase, is one of the genes that is heavily methylated in leukemic cells with an MLL fusion gene. The ALL cell lines were cultured with 5-azacitidine for 7 days, and the expression of CD10 was measured by FACS analysis. Before treatment with 5-azacitidine, surface expression of CD10 was barely detectable in these cell lines. Seven days after treatment with 5-azacitidine, CD10 expression was upregulated in all the tested cell lines (Figure 5a ). As shown in Figure 5b , let-7b expression was increased in MLL fusion-positive cell lines after 5-azacitidine treatment, whereas it did not change significantly in TEL-AML1 fusion-positive cells.
To determine the effects of let-7b overexpression in MLLrearranged leukemic cells, the let-7b genomic region was fused to the 3 0 -UTR of EGFP in the pEGFP-C3 expression vector so that let-7b could be co-transcribed with EGFP in the ALL cell lines. At 24 h after transfection, EGFP-positive cells were separated by FACS sorting (Figure 6a ), and cell growth was assessed using the MTT assay. The expression of let-7b in the EGFP-positive fraction was quantified using the TaqMan miRNA assay. At 24 h after transfection, let-7b expression was elevated in the EGFP-positive fraction of all cell lines examined, irrespective of the MLL gene status (Figure 6b ). The expression of let-7b in the EGFP-positive fractions of these cell lines was sustained at 72 h after transfection.
At 72 h after the induction of let-7b expression, no remarkable differences in cell viability were observed between MLL-rearranged and MLL germline cell lines by FACS analysis (data not shown). The MTT assay showed that cell growth of MLL fusionpositive cell lines was significantly suppressed by let-7b expression (Figure 6c) . No significant differences were observed in the cell lines without MLL fusion after the introduction of let-7b. We assessed whether the apoptotic pathway was activated by let-7b using annexin V staining; however, there was no difference in the annexin V-positive cell populations of the MLL-rearranged and MLL germline cell lines after 6 h of transfection (data not shown).
DISCUSSION
MLL gene rearrangements, leading to the formation of a fusion gene, are frequently observed in infant leukemia cases and in treatment-related leukemia that occurs after chemotherapy for a primary malignancy. The presence of an MLL fusion gene alone is not thought to be sufficient to promote complete leukemogenesis, 30, 31 and overt leukemia with an MLL fusion gene is thought to involve at least one more genetic event (so called 'second hits') other than the formation of the MLL fusion gene, such as the mutation of FLT3 kinase. The acceleration of leukemogenesis by P13688  P13696  P13823  P14473  P14749  P14775  P15114  P15259  P12614  P12745  P13535  P14097  P14624  P15295  P15780  P15912  P17352  4571  5071 an MLL fusion protein and a mutated kinase such as FLT3 32, 33 or RAS 34 also supports the importance of second hits in MLL-related leukemogenesis.
Leukemia with an MLL gene rearrangement frequently involves several additional genetic abnormalities such as deletions and translocations. 35 The MLL fusion protein itself can also be a potent inducer of secondary genetic damage in the presence of genotoxic agents. 36 For these reasons, identification of the primary targets of a leukemogenic MLL fusion protein is essential, because the MLL fusion protein itself and its primary direct effectors involved in leukemogenesis are preferable targets for specific molecular therapy, rather than the effects induced by the secondary genetic abnormalities that vary among leukemic patients and also among leukemic cells in a single patient. 37 As shown in the current study and other reports, 5 let-7b was significantly suppressed in MLL-rearranged ALL samples, compared with germline MLL samples. The let-7 miRNA family has been reported to exhibit tumor suppressor functions, which is consistent with its developmental role in the promotion of cellular differentiation. 38 Many previous reports have described an association between let-7 and human cancer, 8, 15, 16, [39] [40] [41] indicating that let-7 is one of the miRNAs that are downregulated in many cancers. In leukemia, according to a previous study, let-7b expression was significantly downregulated in ALL patients compared with acute myeloid leukemia (AML) patients, with let-7b as the most discriminatory miRNA between ALL and AML. 42 According to this report, it is also true for MLL-rearranged leukemias, because expression of let-7b in 42 These results suggest that a different mechanism may be involved in the regulation of let-7b in AML cells with MLL gene rearrangement, which has a better prognosis than ALL with MLL gene rearrangement.
The mechanism by which let-7b is downregulated in ALL has not yet been elucidated. According to our results, MLL fusion proteins have the capacity to downregulate the expression of let-7b miRNA by suppressing the expression of the upstream RP4-695O20_B.10 gene. This suppression of RP4-695O20_B.10 expression was due to promoter hypermethylation. Here we have identified that DNA hypermethylation is one of the mechanisms underlying the downregulation of let-7b, especially in MLLrearranged ALL.
Several studies have revealed global hypermethylation of promoter CpG islands in MLL-rearranged infant leukemia compared with other types of childhood leukemia. 43, 44 On the other hand, MLL and its fusion proteins are histone methyltransferases, which regulate gene expression by modulating the methylation status of histones rather than that of DNA. Till date, there is no direct evidence that MLL fusion proteins have DNA methylation capability. Elucidation of the mechanism underlying DNA hypermethylation by MLL fusion proteins is an important issue, given the future clinical applications of demethylating agents such as 5-azacitidine in MLL fusion-positive leukemic cases.
Several promising approaches can be expected for the use of the let-7 family as a therapeutic agent for various kinds of cancer. In a previous study, expression of let-7a in the lung using an adenovirus system resulted in a significant reduction in tumor formation. 45 In another study, mice infected with a let-7g-expressing lentivirus exhibited a significant reduction in tumor number and tumor area. 17 Following the introduction of let-7b, the growth of leukemic cells carrying an MLL fusion gene was suppressed in comparison with leukemic cells without MLL fusion (Figure 6c ), indicating that let-7b can suppress the growth of MLL fusion-positive leukemic cells.
Several oncogenes, such as HMGA2, CCND1 and BSG, have been identified as targets of let-7b. 46, 47 Loss of let-7b expression in leukemic cells may result in deregulated expression of some of these oncogenes, providing greater growth advantage to the leukemic cells. Further studies will be required to identify the targets of let-7b in the context of MLL fusion gene-driven leukemogenesis. A possible mechanism of leukemogenesis by MLL fusion proteins via let-7b downregulation is shown in Supplementary Figure 6 .
In conclusion, the complete mechanism underlying the induction of leukemogenesis in infant ALL remains obscure; however, downregulation of the miRNA let-7b by an MLL fusion protein may have a role in this process. The let-7b downregulation appears to be the direct result of the presence of an MLL fusion protein, which acts as a potent inducer of DNA hypermethylation in leukemic cells. 44, 48 In the near future, introduction of let-7b or the effective induction of let-7b expression in leukemic cells using a demethylating agent such as 5-azacitidine may be considered a candidate molecular targeting therapy for infant ALL with MLL gene rearrangements.
